AEON Biopharma announced it has regained compliance with the NYSE American's continued listing standards as of August 3, 2026. The company resolved previous deficiencies related to stockholders' equity following the successful completion of a public offering in July 2026.
Key Details
- Compliance Confirmation: AEON received a letter from NYSE Regulation on August 3, 2026, confirming it meets all continued listing standards, specifically resolving issues under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide.
- Capital Raise: Compliance was achieved after an underwritten public offering that closed in July, generating approximately $13.6 million in aggregate net proceeds and raising stockholders' equity above the required minimum.
- Market Impact: As a result, the "below compliance" (.BC) indicator will be removed from the company's trading symbol, AEON.